Search
Now showing items 1-6 of 6
The bridge between classical and ‘synthetic’/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective
(2019-11-20)
The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new ...
New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues
(2019-04-23)
Purpose of the review: A significant increase in the number, type, and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic ...
An Insight into Z-Drug Abuse and Dependence : An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
(2019-04-01)
BACKGROUND: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone ("Z-drugs") clinical concerns relating to their potential of abuse, ...
A matter of life and death : substance-caused and substance-related fatalities in Ibiza in 2015
(2017-06-28)
Objectives and methods: In the framework of the EU-funded project “EU-Madness,” we collected and analysed all the reports of fatalities directly or indirectly related to substances of abuse registered in Ibiza from January ...
Use of benzylglycinamide by a HIV-seropositive polysubstance user: : the changing pattern of novel psychoactive substance use among youths
(2016-09-30)
A 24-year old woman with multisubstance use since the age of 13, including opioids and cocaine, and long-standing HIV/HCV seropositivity status, presented with psychosis, agitation, and insomnia at the emergency department ...
Phenazepam abuse in the UK : an emerging problem causing serious adverse health problems, including death
(2012-03-09)
OBJECTIVE: Phenazepam (fenazepam; 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; PNZ, 'Bonsai') is a benzodiazepine developed in the former Soviet Union during the 1970s to treat neurological disorders, ...